DK1294382T3 - 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet - Google Patents

7-hydroxy-epiandrosteron med neuroprotektiv aktivitet

Info

Publication number
DK1294382T3
DK1294382T3 DK01945494T DK01945494T DK1294382T3 DK 1294382 T3 DK1294382 T3 DK 1294382T3 DK 01945494 T DK01945494 T DK 01945494T DK 01945494 T DK01945494 T DK 01945494T DK 1294382 T3 DK1294382 T3 DK 1294382T3
Authority
DK
Denmark
Prior art keywords
hydroxy
epiandrosterone
neuroprotective activity
steroids
neuroprotective
Prior art date
Application number
DK01945494T
Other languages
English (en)
Inventor
Ernst Wuelfert
Ashley Ker Pringle
Lars Eric Sundstrom
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Application granted granted Critical
Publication of DK1294382T3 publication Critical patent/DK1294382T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01945494T 2000-06-29 2001-06-29 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet DK1294382T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
PCT/GB2001/002937 WO2002000225A1 (en) 2000-06-29 2001-06-29 7-hydroxyepiandrosterone having neuroprotective activity

Publications (1)

Publication Number Publication Date
DK1294382T3 true DK1294382T3 (da) 2008-11-24

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945494T DK1294382T3 (da) 2000-06-29 2001-06-29 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet

Country Status (24)

Country Link
US (2) US7718639B2 (da)
EP (1) EP1294382B1 (da)
JP (1) JP4942905B2 (da)
KR (1) KR100786284B1 (da)
CN (1) CN100459980C (da)
AT (1) ATE401897T1 (da)
AU (2) AU6770901A (da)
CA (1) CA2414584C (da)
CY (1) CY1108773T1 (da)
CZ (1) CZ299676B6 (da)
DE (1) DE60134979D1 (da)
DK (1) DK1294382T3 (da)
ES (1) ES2310182T3 (da)
GB (1) GB2363983A (da)
HK (1) HK1052300B (da)
HU (1) HU227152B1 (da)
IL (2) IL153541A0 (da)
NO (1) NO327959B1 (da)
PL (1) PL200699B1 (da)
PT (1) PT1294382E (da)
RU (1) RU2307654C2 (da)
SI (1) SI1294382T1 (da)
WO (1) WO2002000225A1 (da)
ZA (1) ZA200300085B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
DK2097437T3 (da) * 2006-11-21 2015-06-29 Umecrine Cognition Ab Anvendelsen af pregnan- og androstansteroider til fremstillingen af en farmaceutisk sammensætning til behandlingen af cns-sygdomme
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
KR960700728A (ko) 1993-03-09 1996-02-24 토마스 메이져 진행성 조직 괴사, 재관류 손상, 세균 전이 및 성인 호흡 장애 증후군의 예방 방법(Methods for Preventing Progressive Tissue Necrosis, Reperfusion Injury, Bacterial Translocation and Adult Respiratory Distress Syndrome)
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5976850A (en) 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
RU2194712C2 (ru) 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0954317B1 (en) 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999024400A1 (en) 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
CA2309855A1 (en) * 1997-11-24 1999-06-03 Katherine D. Gordon Testosterone inhibitors and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
DE50014299D1 (de) 1999-11-02 2007-06-14 Bayer Schering Pharma Ag 18-nor-steroide als selektiv wirksame estrogene
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
US20030166626A1 (en) 2003-09-04
GB2363983A (en) 2002-01-16
HU227152B1 (en) 2010-08-30
EP1294382A1 (en) 2003-03-26
HK1052300A1 (en) 2003-09-11
US20100173883A1 (en) 2010-07-08
IL153541A (en) 2008-03-20
HK1052300B (en) 2009-01-30
HUP0301134A2 (hu) 2003-08-28
JP4942905B2 (ja) 2012-05-30
ES2310182T3 (es) 2009-01-01
IL153541A0 (en) 2003-07-06
CZ200377A3 (cs) 2003-06-18
GB0016022D0 (en) 2000-08-23
EP1294382B1 (en) 2008-07-23
CA2414584C (en) 2009-10-27
PL200699B1 (pl) 2009-01-30
RU2307654C2 (ru) 2007-10-10
AU2001267709B2 (en) 2005-07-28
WO2002000225A1 (en) 2002-01-03
PL359108A1 (en) 2004-08-23
KR100786284B1 (ko) 2007-12-18
JP2004501196A (ja) 2004-01-15
HUP0301134A3 (en) 2006-06-28
ATE401897T1 (de) 2008-08-15
AU6770901A (en) 2002-01-08
CY1108773T1 (el) 2014-04-09
ZA200300085B (en) 2004-04-21
NO20026243D0 (no) 2002-12-27
NO20026243L (no) 2003-02-27
NO327959B1 (no) 2009-10-26
DE60134979D1 (de) 2008-09-04
RU2003102437A (ru) 2005-01-27
CN100459980C (zh) 2009-02-11
CZ299676B6 (cs) 2008-10-15
PT1294382E (pt) 2008-10-21
US7718639B2 (en) 2010-05-18
KR20030034113A (ko) 2003-05-01
CN1440290A (zh) 2003-09-03
SI1294382T1 (sl) 2009-02-28
CA2414584A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
EP1490090A4 (en) ACTIVE SUBSTANCE SYSTEM AND PROCESS FOR THE PROTECTION AND ADMINISTRATION OF ACTIVE SUBSTANCES
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
EP1626980A4 (en) NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
DK1294381T3 (da) Neurobeskyttende 7-beta-hydroxysteroider
NO20015897L (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20024598D0 (no) Farmasöytisk aktive pyrrolidinderivater
DK1294382T3 (da) 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
AU2002223655A1 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
DE60036356D1 (de) Düse sowie zugehöriger Absauger
AU2001291877A1 (en) N-alkoxyalkyl-substituted benzimidazoles and the use thereof as an agent againstparasitic protozoans
FI971549A0 (fi) Polyol- och komplexa estrar i synnerhet foer anvaendning med fluorerade koeldmedel
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
TW401929U (en) Device for protecting the chair back screen from being excessively raised up and damaged
FI991103L (fi) Menetelmä ja järjestely luvattoman käytön estämiseksi langattomasti
AU6846700A (en) Benzoxazine derivatives and their therapeutic use
SE9903582D0 (sv) Sätt vid framställning av band samt valsverkslinje
AU1414101A (en) Neuroprotective agents and methods related thereto